News

  • 19 December 2011

    Raptor Pharmaceutical agrees RP104 research deal

    Raptor Pharmaceutical has entered into a cooperative research and development agreement with the National Institute of Diabetes and Digestive and Kidney Diseases to conduct a Phase IIb clinical trial of...

  • 18 December 2011

    FDA clears Vertex Kalydeco NDA

    The US Food and Drug Administration (FDA) has granted Vertex Pharmaceuticals' New Drug Application (NDA) and its request for a six-month Priority Review of its Kalydeco (ivacaftor, VX-770) drug, used...

  • 18 December 2011

    Pfizer Lyrica capsules meet co-primary endpoints

    Pfizer has announced that its Lyrica (pregabalin) capsules have met each of its three co-primary endpoints in the Phase III study evaluating it in patients with restless legs syndrome.

  • 15 December 2011

    BioSante reports LibiGel efficacy trials data

    BioSante Pharmaceuticals has announced the top-line results from its two pivotal Phase III efficacy trials of LibiGel (testosterone gel), used for the treatment of postmenopausal women who suffer from female...

  • 14 December 2011

    TH-302 shows efficacy against leukemia: Threshold reports

    Threshold Pharmaceuticals' TH-302 drug has produced promising clinical trial results in the Phase I study performed at MD Anderson's Cancer Center in Houston, US, for treating patients with advanced leukemias.

  • 13 December 2011

    Novartis reports Phase III study results of INC424

    Novartis has presented the supplementary results from two pivotal Phase III trials investigating its INC424 (ruxolitinib) drug, a Janus kinase (JAK) inhibitor that is used to treat patients with myelofibrosis.

Close
Close
Close

Go Top